Arequipa, Peru Clinical Trials

A listing of Arequipa, Peru clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17 clinical trials
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

rituximab
acalabrutinib
cyclin d1
bendamustine
Research Site
 (0.0 away) Contact site
  • 1270 views
  • 24 Jul, 2021
  • +250 other locations
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer …

Research Site
 (0.0 away) Contact site
  • 712 views
  • 04 Jun, 2021
  • +148 other locations
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

Research Site
 (0.0 away) Contact site
  • 50 views
  • 02 Aug, 2021
  • +223 other locations
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced …

etoposide
paclitaxel
carboplatin
metastasis
durvalumab
Hospital Nacional Carlos Alberto Seguin Escobedo ESSALUD ( Site 0604)
 (0.9 away) Contact site
  • 51 views
  • 01 Aug, 2021
  • +187 other locations
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)

mammogram
measurable disease
cancer
paclitaxel
triple-negative breast cancer
Research Site
 (0.0 away) Contact site
  • 1387 views
  • 30 Jul, 2021
  • +309 other locations
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung cancers are due …

kinase inhibitor
non-squamous non-small cell lung cancer
carboplatin
growth factor
pemetrexed
Research Site
 (0.0 away) Contact site
  • 811 views
  • 21 Jul, 2021
  • +171 other locations
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal Pancreatic or Colorectal Cancer

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer

Research Site
 (0.9 away) Contact site
  • 143 views
  • 17 Jul, 2021
  • +185 other locations
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment.

Research Site
 (0.0 away) Contact site
  • 0 views
  • 18 Jul, 2021
  • +185 other locations
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.

Centro Medico Monte Carmelo SCRLtda
 (0.0 away) Contact site
  • 4293 views
  • 01 Aug, 2021
  • +502 other locations
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.

measurable disease
cancer
mk-3475
pembrolizumab
cancer of the ovary
Hospital Nacional Carlos Alberto Seguin Escobedo ESSALUD ( Site 3206)
 (0.9 away) Contact site
  • 16 views
  • 01 Aug, 2021
  • +148 other locations